Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?

Abstract Breast cancer (BrCa) is a complex and heterogeneous disease with diverse molecular subtypes, leading to varied clinical outcomes and posing significant treatment challenges. The increasing global burden of BrCa, particularly in low- and middle-income countries, underscores the urgent need f...

Full description

Saved in:
Bibliographic Details
Main Authors: Tryambak Pratap Srivastava, Ruby Dhar, Subhradip Karmakar
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Reproductive Biology and Endocrinology
Subjects:
Online Access:https://doi.org/10.1186/s12958-024-01338-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585288576139264
author Tryambak Pratap Srivastava
Ruby Dhar
Subhradip Karmakar
author_facet Tryambak Pratap Srivastava
Ruby Dhar
Subhradip Karmakar
author_sort Tryambak Pratap Srivastava
collection DOAJ
description Abstract Breast cancer (BrCa) is a complex and heterogeneous disease with diverse molecular subtypes, leading to varied clinical outcomes and posing significant treatment challenges. The increasing global burden of BrCa, particularly in low- and middle-income countries, underscores the urgent need for more effective therapeutic strategies. The androgen receptor (AR), expressed in a substantial proportion of breast cancer cases, has emerged as a potential biomarker and therapeutic target. In breast cancer, AR exhibits diverse functions across subtypes, often interacting with other hormone receptors, thereby influencing tumor progression and treatment responses. This intricate interplay is further complicated by the presence of constitutively expressed AR splice variants (AR-Vs) that drive resistance to AR-targeting therapies through structural rearrangements in the domains and activation of aberrant signaling pathways. Although AR-targeting drugs, initially developed for prostate cancer (PCa), have shown promise in AR-positive breast cancer, significant gaps remain in understanding AR’s precise functions and therapeutic potential. The systemic management of breast cancer is guided primarily by theranostic biomarkers; ER, PR, HER2, and Ki67 which also dictate the breast cancer classification. The ubiquitous expression of AR in BrCa and the emergence of AR-Vs can assist the management of disease complementing the standard of care. This article provides a comprehensive overview of AR and its splice variants in the context of breast cancer, highlighting their prognostic and predictive value across different subtypes looking beyond the conventional ER, PR, and HER2 status. This review also raises the possibility of using AR splice variants in predicting tumor aggressiveness. From the settings of developing nations, this may provide useful insight by integrating recent advances in AR-targeted therapies and exploring their translational potential, emphasizing the critical need for further research to optimize AR-based therapeutic strategies for breast cancer management.
format Article
id doaj-art-6ee2ed79c98943bf811e4193dd08e18f
institution Kabale University
issn 1477-7827
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series Reproductive Biology and Endocrinology
spelling doaj-art-6ee2ed79c98943bf811e4193dd08e18f2025-01-26T12:58:01ZengBMCReproductive Biology and Endocrinology1477-78272025-01-0123111710.1186/s12958-024-01338-zLooking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?Tryambak Pratap Srivastava0Ruby Dhar1Subhradip Karmakar2Department of Biochemistry, All India Institute of Medical SciencesDepartment of Biochemistry, All India Institute of Medical SciencesDepartment of Biochemistry, All India Institute of Medical SciencesAbstract Breast cancer (BrCa) is a complex and heterogeneous disease with diverse molecular subtypes, leading to varied clinical outcomes and posing significant treatment challenges. The increasing global burden of BrCa, particularly in low- and middle-income countries, underscores the urgent need for more effective therapeutic strategies. The androgen receptor (AR), expressed in a substantial proportion of breast cancer cases, has emerged as a potential biomarker and therapeutic target. In breast cancer, AR exhibits diverse functions across subtypes, often interacting with other hormone receptors, thereby influencing tumor progression and treatment responses. This intricate interplay is further complicated by the presence of constitutively expressed AR splice variants (AR-Vs) that drive resistance to AR-targeting therapies through structural rearrangements in the domains and activation of aberrant signaling pathways. Although AR-targeting drugs, initially developed for prostate cancer (PCa), have shown promise in AR-positive breast cancer, significant gaps remain in understanding AR’s precise functions and therapeutic potential. The systemic management of breast cancer is guided primarily by theranostic biomarkers; ER, PR, HER2, and Ki67 which also dictate the breast cancer classification. The ubiquitous expression of AR in BrCa and the emergence of AR-Vs can assist the management of disease complementing the standard of care. This article provides a comprehensive overview of AR and its splice variants in the context of breast cancer, highlighting their prognostic and predictive value across different subtypes looking beyond the conventional ER, PR, and HER2 status. This review also raises the possibility of using AR splice variants in predicting tumor aggressiveness. From the settings of developing nations, this may provide useful insight by integrating recent advances in AR-targeted therapies and exploring their translational potential, emphasizing the critical need for further research to optimize AR-based therapeutic strategies for breast cancer management.https://doi.org/10.1186/s12958-024-01338-zAndrogen receptorBreast cancerSplice variantsAR-V7AndrogensAR signaling
spellingShingle Tryambak Pratap Srivastava
Ruby Dhar
Subhradip Karmakar
Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
Reproductive Biology and Endocrinology
Androgen receptor
Breast cancer
Splice variants
AR-V7
Androgens
AR signaling
title Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
title_full Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
title_fullStr Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
title_full_unstemmed Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
title_short Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
title_sort looking beyond the er pr and her2 what s new in the arsenal for combating breast cancer
topic Androgen receptor
Breast cancer
Splice variants
AR-V7
Androgens
AR signaling
url https://doi.org/10.1186/s12958-024-01338-z
work_keys_str_mv AT tryambakpratapsrivastava lookingbeyondtheerprandher2whatsnewinthearsenalforcombatingbreastcancer
AT rubydhar lookingbeyondtheerprandher2whatsnewinthearsenalforcombatingbreastcancer
AT subhradipkarmakar lookingbeyondtheerprandher2whatsnewinthearsenalforcombatingbreastcancer